Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
Abstract Aims As an extension of a phase 2/3 study evaluating the efficacy and safety of lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d for 4 weeks in Japanese patients aged 6‐17 years with attention‐deficit/hyperactivity disorder (ADHD), this study evaluated its long‐term safety and efficacy....
Main Authors: | Hironobu Ichikawa, Tasuku Miyajima, Yushiro Yamashita, Masakazu Fujiwara, Akimasa Fukushi, Kazuhiko Saito |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Neuropsychopharmacology Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/npr2.12091 |
Similar Items
-
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
by: Jain Rakesh, et al.
Published: (2011-11-01) -
A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
by: James Ermer, et al.
Published: (2020-03-01) -
Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa
by: Laura Dixon, et al.
Published: (2023-05-01) -
Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran
by: Amirmohammad Tajik, et al.
Published: (2023-10-01) -
Influence of Lisdexamfetamine Dimesylate on Early Ejaculation—Results from a Double-Blind Randomized Clinical Trial
by: Mohammad Haghighi, et al.
Published: (2021-07-01)